Protective and therapeutic use of digestion resistant starch (MSPrebiotic®) in a pig model of experimental colitis

抗消化淀粉 (MSPrebiotic®) 在实验性结肠炎猪模型中的保护和治疗用途

• 批准号: 521785-2017
• 负责人: Khafipour, Ehsan
• 金额: $ 1.82万
• 依托单位: University of Manitoba
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=640759
• 关键词: Protective; therapeutic; use; digestion; resistant

Emerging therapeutics are used to alleviate intestinal inflammation and microbial dysbiosis including dietarysupplies of prebiotics and probiotics. Digestion resistant starch (DRS) represents a diverse range of dietarycarbohydrates bypassing into the lower gut where it undergoes microbial fermentation. DRS has beeninvestigated in the past years for its effects on gut health via balancing the microbiota composition and shortchain fatty acid levels. It is speculated that DRS can reduce colitis symptoms and pathology throughmodification of the gut microbiota, possible regulation of local inflammatory cytokines and its effects onmucosal barrier system.MSPrebiotic Inc., a Manitoba-based global biotechnological company, has developed a popular potato DRSproduct named MSPrebiotic®. The company is seeking a project to optimize their recommendations foradministration of MSPrebiotic® either as a preventative and/or therapeutic tool for reducing gut inflammationand improving gut health.Here, we investigate the protective and therapeutic effects of DRS (MSPrebiotic®) in a pig model ofexperimental colitis. Pigs will receive 5 different treatments including 1) basal control diet, 2) colitis-inducingdiet (1% carrageenan gum), 3) DRS diet, 4) colitis-inducing diet for 2 weeks followed by introduction of DRSdiet (to measure therapeutic effect of DRS), and 5) DRS diet for 2 weeks followed by a colitis-inducing diet (tomeasure the protective effect of DRS). Fecal consistency and large intestine histology will be used as measuresof gastrointestinal inflammation. Blood samples will be analyzed for systemic inflammatory markers. Gutmicrobiota profile will be assed using 16S rRNA gene sequencing in-house followed by prediction offunctional capacity of the microbial community using PICRUSt. The outcome of this research will help thecompany to optimize their recommendations for the use of MSPrebiotic® as a preventative and/or therapeuticapproach for reducing gut inflammation and improving gut health.

新兴的治疗方法用于缓解肠道炎症和微生物生态失调，包括益生元和益生菌的饮食供应。抗消化淀粉（DRS）代表了多种膳食碳水化合物绕过下肠道，在那里进行微生物发酵。在过去的几年里，DRS通过平衡微生物群组成和短链脂肪酸水平来研究其对肠道健康的影响。据推测，DRS可以通过改变肠道微生物群，可能调节局部炎症细胞因子及其对粘膜屏障系统的影响来减轻结肠炎症状和病理。一家总部位于马尼托巴的全球生物技术公司，开发了一种名为MSPrebiotic®的受欢迎的马铃薯DRS产品。该公司正在寻求一个项目，以优化他们的建议，管理MSPrebiotic®无论是作为预防和/或治疗工具，以减少肠道炎症和改善肠道健康。在这里，我们调查DRS（MSPrebiotic®）的保护和治疗作用在猪模型的实验性结肠炎。猪将接受5种不同的处理，包括1）基础对照饮食，2）结肠炎诱导饮食（1%角叉菜胶），3）DRS饮食，4）结肠炎诱导饮食2周，随后引入DRS饮食（以测量DRS的治疗效果），和5）DRS饮食2周，随后结肠炎诱导饮食（以测量DRS的保护效果）。粪便稠度和大肠组织学将被用作胃肠道炎症的指标。将分析血液样本的全身炎症标志物。将使用内部16 S rRNA基因测序评估肠道微生物群特征，然后使用PICRUSt预测微生物群落的功能能力。这项研究的结果将帮助公司优化他们的建议，使用MSPrebiotic®作为预防和/或治疗方法，以减少肠道炎症和改善肠道健康。